The Claim
Adding ezetimibe to statin therapy in patients at high cardiovascular risk reduces the incidence of non-fatal heart attacks by 17 fewer events per 1,000 patients treated over six years.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people at high risk of heart disease, adding ezetimibe to statin therapy results in 17 fewer non-fatal heart attacks per 1,000 patients over six years compared to statin therapy alone.
See the scientific wording
Adding ezetimibe to statin therapy in patients at high cardiovascular risk likely reduces the incidence of non-fatal heart attacks by 17 fewer events per 1,000 patients treated over six years, based on moderate-certainty evidence from randomized controlled trials, suggesting a clinically modest but meaningful benefit for preventing non-lethal cardiovascular events.
Ezetimibe blocks cholesterol absorption in the gut, so less cholesterol enters the bloodstream. This lowers the amount of LDL cholesterol circulating in the blood. Lower LDL cholesterol means less buildup of fatty plaques inside artery walls. These plaques become more stable and less likely to break open, which prevents blockages that cause heart attacks.
What the research says
1 studyFor people at high risk of heart disease, adding ezetimibe to their statin pill slightly lowers the chance of having a non-fatal heart attack—about 17 fewer heart attacks per 1,000 people over six years. It’s a small benefit, but it’s real and backed by solid research.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.